The survival rate comparison of non small cell lung carcinoma patients who are given by epidermal growth factor receptor-tyrosin kinase inhibitor and those given by first-line chemotherapy treatment. NMSJ [Internet]. 2022 Jan. 20 [cited 2026 Aug. 21];6(2):103-15. Available from: https://journal-598.unhas.ac.id/index.php/jmednus/article/view/18857